title: Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells.
abstract: NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors. Recent work supports their use in multiple myeloma by showing that ex vivo antigen-specific expanded T cells traffic to and persist in bone marrow, are well tolerated, and produce promising response rates when infused after stem cell transplantation.
authors.affiliation: Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, 31008 Pamplona, Spain. Electronic address: sanmiguel@unav.es.
authors.forename: Jesus F
authors.initials: JF
authors.lastname: San Miguel
authors.affiliation: Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, 31008 Pamplona, Spain.
authors.forename: Bruno
authors.initials: B
authors.lastname: Paiva
authors.affiliation: Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, 31008 Pamplona, Spain.
authors.forename: Juan-Jose
authors.initials: JJ
authors.lastname: Lasarte
mesh_terms: D001853:Bone Marrow / Q000276:immunology; D060846:Cell Engineering / Q000379:methods; D006801:Humans; D009101:Multiple Myeloma / Q000276:immunology*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D011948:Receptors, Antigen, T-Cell